Medesis Pharma (DB:76D) - Stock Price, News & Analysis

76D Stock Overview

Operates as a biopharmaceutical company. More details

76D fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Does not have a meaningful market cap (€2M)

Makes less than USD$1m in revenue (€64K)

Earnings have declined by 26% per year over past 5 years

+ 2 more risks

Medesis Pharma S.A. Competitors

co.don

XTRA:CNW

€6.5m

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Epigenomics

DB:ECX

€1.1m

Price History & Performance

Summary of all time highs, changes and price drops for Medesis Pharma
Historical stock prices
Current Share Price	€0.34
52 Week High	€1.80
52 Week Low	€0.27
Beta	0.049
11 Month Change	0%
3 Month Change	-70.31%
1 Year Change	-57.50%
33 Year Change	-93.41%
5 Year Change	n/a
Change since IPO	-96.81%

Recent updates

Shareholder Returns

	76D	DE Biotechs	DE Market
7D	-8.1%	-0.2%	0.8%
1Y	-57.5%	-16.9%	9.1%

Return vs Industry: 76D underperformed the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: 76D underperformed the German Market which returned 8.5% over the past year.

Price Volatility

Is 76D's price volatile compared to industry and market?
76D volatility
76D Average Weekly Movement	35.4%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 76D's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 76D's weekly volatility has increased from 22% to 35% over the past year.

About the Company

Founded	Employees	CEO	Website
2003	10	Jean-Claude Maurel	www.medesispharma.com

Medesis Pharma S.A. operates as a biopharmaceutical company. The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma.

Medesis Pharma S.A. Fundamentals Summary

How do Medesis Pharma's earnings and revenue compare to its market cap?
76D fundamental statistics
Market cap	€2.17m
Earnings (TTM)	-€3.13m
Revenue (TTM)	€63.64k

34.1x

P/S Ratio

-0.7x

P/E Ratio

Is 76D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
76D income statement (TTM)
Revenue	€63.64k
Cost of Revenue	€2.13m
Gross Profit	-€2.07m
Other Expenses	€1.07m
Earnings	-€3.13m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.62
Gross Margin	-3,244.94%
Net Profit Margin	-4,924.73%
Debt/Equity Ratio	-64.7%

How did 76D perform over the long term?

See historical performance and comparison

Medesis Pharma DB:76D Stock Report